Early administration of the antiviral drug remdesivir, marketed as Veklury by Gilead Sciences, is associated with a significantly reduced risk of in-hospital mortality among hospitalized adults with COVID-19 who have preexisting renal or hepatic disease, according to a study presented by Patrick Godwin, MD, and colleagues, offering critical survival data for vulnerable patient populations historically excluded from clinical trials.
Evaluating High-Risk Subpopulations in Real-World Cohorts
Individuals infected with SARS-CoV-2 who present with underlying hepatic or renal comorbidities are at higher mortality risk than the overall population. To address data gaps in clinical decision-making for these high-risk groups, researchers conducted a retrospective analysis of U.S. medical claims and hospital chargemaster data. The study evaluated clinical outcomes among adult patients who initiated remdesivir treatment upon hospital admission or within the first two days of hospitalization.
To eliminate demographic and clinical confounding factors, the research team utilized coarsened exact matching alongside 1:1 propensity score matching. Within the matched cohorts, the renal group comprised 13,798 patients with an overall mortality rate of 6.05%, while the hepatic cohort included 4,968 patients exhibiting a mortality rate of 4.59%. Statistical evaluation demonstrated survival advantages tied to early antiviral intervention.
Quantifying the Survival Benefit Across Organ Dysfunction
The retrospective data parsing yielded distinct hazard ratios for patients based on their specific organ pathology. Among patients with underlying renal disease, the administration of remdesivir correlated with a 15% reduction in mortality risk, supported by a hazard ratio of 0.85 and a 95% confidence interval ranging from 0.75 to 0.96. The protective association proved more pronounced in patients with hepatic comorbidities, who experienced a 33% lower risk of in-hospital death, reflected by a hazard ratio of 0.67 and a 95% confidence interval of 0.53 to 0.85.
- Renal Cohort: 13,798 matched patients; 15% lower mortality risk (HR 0.85, 95% CI 0.75–0.96).
- Hepatic Cohort: 4,968 matched patients; 33% lower mortality risk (HR 0.67, 95% CI 0.53–0.85).
- Oxygen Status: Survival benefits persisted among patients requiring supplemental oxygen upon admission.
- Hepatic Patients: Hepatic patients not requiring supplemental oxygen also saw significant mortality reductions (HR 0.55, 95% CI 0.34–0.89).
As noted by Dr. Godwin and co-authors in their findings, individuals hospitalized with SARS-CoV-2 infection and underlying hepatic or renal comorbidity treated with the antiviral realized an in-hospital survival benefit over those not similarly treated. This therapeutic advantage extended to patients receiving supplemental oxygen at the time of admission. Furthermore, among hepatic patients presenting without supplemental oxygen needs, early remdesivir deployment lowered mortality rates with a hazard ratio of 0.55.
Re-evaluating Safety Profiles in Organ Impairment
Clinical trials previously excluded patients with renal or hepatic toxicity concerns. However, the accumulation of real-world evidence continues to reshape clinical consensus. A 2025 meta-analysis published in BMC Infectious Diseases reported that remdesivir utilization among patients suffering from severe renal impairment correlated with a lower incidence of kidney injury, registering a risk ratio of 0.51 with a 95% confidence interval of 0.27 to 0.97. That analysis identified no significant elevation in hepatic disorders or overall mortality, reinforcing a safety profile capable of supporting patients previously excluded from clinical trials.
The alignment between real-world claims analyses and broader 2025 safety evaluations provides clinicians with metrics regarding the administration of the drug in organ-compromised cohorts. By demonstrating survival gains and an absence of exacerbated renal toxicity, the data broadens the operational window for deploying antivirals against SARS-CoV-2 in complex inpatient environments.
Related reading
